Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Helix Biopharma Corp. (HBPCF) had Return on Tangible Equity of 43.39% for the most recently reported fiscal quarter, ending 2025-10-31.
| Income Statement Financials | |
-- |
|
$-0.73M |
|
-- |
|
-- |
|
$0.67M |
|
$-0.67M |
|
$-0.06M |
|
$-0.73M |
|
$-0.73M |
|
$-0.73M |
|
$-0.73M |
|
$-0.73M |
|
$-0.73M |
|
$-0.67M |
|
$-0.67M |
|
75.87M |
|
75.87M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$0.49M |
|
$0.00M |
|
$13.25M |
|
$13.74M |
|
$2.16M |
|
-- |
|
-- |
|
$2.16M |
|
$11.58M |
|
$-1.67M |
|
$11.58M |
|
76.38M |
|
| Cash Flow Statement Financials | |
$-0.88M |
|
-- |
|
$1.19M |
|
$0.05M |
|
$0.36M |
|
$0.31M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.23 |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.27% |
|
|
Return on Tangible Equity |
43.39% |
-5.29% |
|
-6.27% |
|
$0.15 |
|
$-0.01 |
|
$-0.01 |
|